We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis

By LabMedica International staff writers
Posted on 01 Sep 2026

Long COVID presents with heterogeneous, persistent symptoms that complicate clinical assessment and case definition. More...

A lack of a definitive diagnostic test forces clinicians to exclude alternative etiologies before assigning a diagnosis. Saliva offers a non-invasive sample type that can be collected repeatedly across disease stages, making it well suited for biomarker research aimed at clarifying disease status over time. Building on this potential, a new project will examine salivary biomarkers to support diagnosis and risk stratification in Long COVID.

UNC Adams School of Dentistry (University of North Carolina; Chapel Hill, NC, USA) has received an R01 grant from the National Institutes of Health (NIH) to determine whether biomarkers in saliva can diagnose long COVID and predict which acutely infected patients are likely to develop persistent symptoms. The effort will also analyze saliva collected during acute COVID-19 to evaluate signatures associated with future long COVID. The goal is to translate salivary changes into clinically actionable markers for patient classification.

The team will analyze saliva for immune and host-response signals, including proteins, metabolic mediators, and microbes, and use a machine learning pipeline to identify oral signatures of disease. By processing large patient datasets, the models are expected to improve understanding of Long COVID pathogenesis and help distinguish recovery from persistent illness. The project builds on earlier work in which the group evaluated antiseptic rinses to reduce salivary viral load in dental settings and, after collecting saliva from hundreds of patients, began investigating how SARS-CoV-2 affects the oral immune environment.

Study plans include recalling additional participants and enrolling newly infected patients who will be followed through serial saliva collection. At least three months after infection, participants will complete validated symptom questionnaires and be grouped as fully recovered or showing signs of Long COVID. Their saliva samples, linked with health histories, will then be analyzed to determine how salivary proteins, metabolic mediators, and microbes are associated with Long COVID outcomes.

Preliminary analyses of banked early-infection samples showed altered salivary protein and metabolite profiles among individuals who later developed Long COVID. Proteomic testing also identified dozens of differentially expressed proteins related to oral inflammation, oxidative stress responses, and immune dysregulation. If validated, the researchers note, these salivary biomarkers could support diagnostic and prognostic tools and help identify higher-risk patients for more proactive management during acute infection.

“Based on preliminary results, patients who develop long COVID had significantly altered salivary protein and metabolite profiles relative to patients who recovered. Proteomics results identified 47 differentially expressed proteins between severe long COVID patients and controls. There were several unexpected highly abundant proteins associated with oral inflammation, oxidative stress response, and immune dysregulation. These are interdependent mechanisms perpetuating a chronic cycle of cellular damage that may drive Long COVID pathology that we could identify in saliva during acute infection- which is pretty amazing!” said Laura Jacox, DMD, PhD, MS.

“For patients who have long-term long COVID symptoms, it would be wonderful to provide a non-invasive diagnostic test. This would save efforts and costs that are currently being spent ruling out other potential causes, and a test provides comfort to patients and informs providers,” said Jacox.

Related Links
UNC Adams School of Dentistry


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.